Skip to content
MarketNewsAPI
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PONIF$0.12-0.00(-3.70%)Silver Pony Announces Closing of Up-Sized $1,600,015 Strategic Unit Offering[6:15:00 PM ET]ELME$0.07-1.70(-96.19%)Elme Communities Announces Suspended NYSE Trading; Anticipates Trading Will Begin OTC Effective October 26, 2026[5:47:00 PM ET]HHH$72.57+3.08(+4.43%)Howard Hughes Holdings Set to Join S&P SmallCap 600 Howard Hughes Holdings Inc. (NYSE: HHH) will replace Arcosa Inc. (NYSE: ACA) in the S&P SmallCap 600 effective prior to the opening of trading on...[5:45:00 PM ET]ALGRF$0.400.00(0.00%)Algo Grande Commissions Independent NI 43-101 Update to Capture First Year of Progress at Adelita[5:30:00 PM ET]ZEFIF$0.45+0.02(+3.56%)Zefiro Announces Closing of Non-Brokered Private Placement for Gross Proceeds of Approximately C$5.0 Million[5:29:00 PM ET]BLK$1,118.50-18.79(-1.65%)BlackRock® Canada Announces the Termination of iShares Convertible Bond Index ETF[5:23:34 PM ET]ITFS$1.43-0.02(-1.10%)Itafos Announces Release Date for Q3 2026 Results and Business Update Webcast[5:15:00 PM ET]FAGI$0.01-0.00(-13.33%)Full Alliance Group, Inc (OTC:FAGI) YAHBEE Highlights Community-Commerce Model for Agentic Commerce Era[5:15:00 PM ET]TGT$152.76-5.35(-3.38%)Vital Farms Introduces a Higher Standard for Free-Range Eggs Through Limited Pilot at Select Target Retail Stores[5:05:00 PM ET]NU$15.23+0.50(+3.39%)Notice to Market: Nu Holdings Ltd.[5:03:00 PM ET]POR$44.55-0.35(-0.78%)Portland General Electric Declares Dividend[5:00:00 PM ET]ANTX$3.55-0.09(-2.47%)AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)[5:00:00 PM ET]

BIIB · NASDAQ

Biogen Inc.

$246.01 -7.95 (-3.13%)

Company overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE.

Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NASDAQ
Market cap
$36.3B
Employees
7,605
Headquarters
Cambridge, MA
Website
biogen.com
CEO
Christopher A. Viehbacher
Listed
September 17, 1991
P/E
26.26
Dividend yield
0.00%

Company financials

Revenue
$9.9B
Gross profit
$6.9B
Operating income
$1.5B
EBITDA
$2.8B
Net income
$1.4B
EPS
$9.37
Total assets
$29.5B
Total debt
$6.6B
Gross margin
69.77%
Net margin
13.92%
Earnings yield
3.81%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

175.69196.13216.57237.00257.44
BIIB 1D NASDAQ O240.61H254.41L240.02C253.84+12.86 (+5.34%)Vol2.24M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
BIIB Stock news Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains? Zacks Investment Research
BIIB Stock news The Week Ahead: Wall Street Awaits October Fed Decision Schaeffers Research
BIIB Press release Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week GlobeNewswire
BIIB Stock news Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade) Seeking Alpha
BIIB Stock news Wall Street Breakfast Podcast: GTA 6 Threat Sends Token Up Seeking Alpha
FHLC Stock news Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE? Fool - Investing News
BIIB Stock news Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says Proactive Investors
BIIB Stock news Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? Zacks Investment Research
BIIB Stock news Biogen's experimental lupus drug shows benefit against skin symptoms Reuters
BIIB Press release Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus GlobeNewsWire
BIIB Stock news Biogen (NASDAQ:BIIB) Reaches New 12-Month High – Still a Buy? Defense World
BIIB Stock news Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs? Zacks Investment Research
BIIB Press release Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN GlobeNewsWire
BIIB Press release LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) GlobeNewswire
BIIB Stock news Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience MarketBeat
BIIB Stock news Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
BIIB Stock news Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology MarketBeat
BIIB Stock news Biogen (NASDAQ:BIIB) versus NewAmsterdam Pharma (NASDAQ:NAMS) Financial Analysis Defense World
BIIB Stock news Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Seeking Alpha
BIIB Press release A Micro-Cap Biotech Just Cleared a Milestone Most Never GlobeNewswire
See more
FAQ

Questions about Biogen Inc.

What does Biogen Inc. do?
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE.
What is BIIB's market cap?
Biogen Inc. (BIIB) is a listed stock with a live quote. The latest market cap on this page is $36.3B.
Where is Biogen Inc. headquartered?
Biogen Inc. is headquartered in Cambridge, MA.
How do I get BIIB news from the API?
Call GET /v1/news?tickers=BIIB. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does BIIB news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for BIIB, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the BIIB price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs